Literature DB >> 27678134

Haemodynamic changes in hepatocellular carcinoma and liver parenchyma under balloon occlusion of the hepatic artery.

Fumie Sugihara1, Satoru Murata2, Tatsuo Ueda1, Daisuke Yasui1, Hidenori Yamaguchi1, Izumi Miki1, Chiaki Kawamoto3, Eiji Uchida4, Shin-Ichiro Kumita1.   

Abstract

OBJECTIVES: To investigate haemodynamic changes in hepatocellular carcinoma (HCC) and liver under hepatic artery occlusion.
METHODS: Thirty-eight HCC nodules in 25 patients were included. Computed tomography (CT) during hepatic arteriography (CTHA) with and without balloon occlusion of the hepatic artery was performed. CT attenuation and enhancement volume of HCC and liver with and without balloon occlusion were measured on CTHA. Influence of balloon position (segmental or subsegmental branch) was evaluated based on differences in HCC-to-liver attenuation ratio (H/L ratio) and enhancement volume of HCC and liver.
RESULTS: In the segmental group (n = 20), H/L ratio and enhancement volume of HCC and liver were significantly lower with balloon occlusion than without balloon occlusion. However, in the subsegmental group (n = 18), H/L ratio was significantly higher and liver enhancement volume was significantly lower with balloon occlusion; HCC enhancement volume was similar with and without balloon occlusion. Rate of change in H/L ratio and enhancement volume of HCC and liver were lower in the segmental group than in the subsegmental group. There were significantly more perfusion defects in HCC in the segmental group.
CONCLUSIONS: Hepatic artery occlusion causes haemodynamic changes in HCC and liver, especially with segmental occlusion. KEY POINTS: • Hepatic artery occlusion causes haemodynamic changes in hepatocellular carcinoma and liver. • Segmental occlusion decreased rate of change in hepatocellular carcinoma-to-liver attenuation ratio. • Subsegmental occlusion increased rate of change in hepatocellular carcinoma-to-liver attenuation ratio. • Hepatic artery occlusion decreased enhancement volume of hepatocellular carcinoma and liver. • Hepatic artery occlusion causes perfusion defects in hepatocellular carcinoma.

Entities:  

Keywords:  Balloon occlusion; Haemodynamics; Hepatocellular carcinoma; Multidetector computed tomography; Therapeutic chemoembolization

Mesh:

Year:  2016        PMID: 27678134     DOI: 10.1007/s00330-016-4573-2

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  23 in total

1.  Communicating arcade between the right and left hepatic arteries: evaluation with CT and angiography during temporary balloon occlusion of the right or left hepatic artery.

Authors:  Takayuki Tohma; Akihiro Cho; Shinichi Okazumi; Harufumi Makino; Kiyohiko Shuto; Ryoyu Mochiduki; Katsuhiko Matsubara; Hisashi Gunji; Takenori Ochiai
Journal:  Radiology       Date:  2005-08-18       Impact factor: 11.105

2.  Quantitation of the hepatic arterial buffer response to graded changes in portal blood flow.

Authors:  W W Lautt; D J Legare; W R Ezzat
Journal:  Gastroenterology       Date:  1990-04       Impact factor: 22.682

3.  [Balloon-occluded arterial infusion--a new method for administration of anticancer drugs (author's transl)].

Authors:  R Yamada; S Yamaguchi; H Nakatsuka; K Nakamura; M Sato; N Kobayashi; S Takashima; H Sangen
Journal:  Nihon Igaku Hoshasen Gakkai Zasshi       Date:  1981

4.  Newer anatomy of the liver and its variant blood supply and collateral circulation.

Authors:  N A Michels
Journal:  Am J Surg       Date:  1966-09       Impact factor: 2.565

5.  Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective balloon-occluded transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure.

Authors:  Toshiyuki Irie; Masashi Kuramochi; Nobuyuki Takahashi
Journal:  Cardiovasc Intervent Radiol       Date:  2012-09-21       Impact factor: 2.740

6.  Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma.

Authors:  Hirotaka Arai; Takehiko Abe; Hisashi Takayama; Mitsuo Toyoda; Takashi Ueno; Satoru Kakizaki; Ken Sato
Journal:  Hepatol Res       Date:  2014-09-05       Impact factor: 4.288

Review 7.  Hepatocellular carcinoma.

Authors:  Alejandro Forner; Josep M Llovet; Jordi Bruix
Journal:  Lancet       Date:  2012-02-20       Impact factor: 79.321

8.  Prognosis of hepatocellular carcinoma: the BCLC staging classification.

Authors:  J M Llovet; C Brú; J Bruix
Journal:  Semin Liver Dis       Date:  1999       Impact factor: 6.115

Review 9.  Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials.

Authors:  Calogero Cammà; Filippo Schepis; Ambrogio Orlando; Maddalena Albanese; Lillian Shahied; Franco Trevisani; Pietro Andreone; Antonio Craxì; Mario Cottone
Journal:  Radiology       Date:  2002-07       Impact factor: 11.105

Review 10.  Interventional treatment for unresectable hepatocellular carcinoma.

Authors:  Satoru Murata; Takahiko Mine; Fumie Sugihara; Daisuke Yasui; Hidenori Yamaguchi; Tatsuo Ueda; Shiro Onozawa; Shin-ichiro Kumita
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

View more
  1 in total

1.  Computational Modeling of the Liver Arterial Blood Flow for Microsphere Therapy: Effect of Boundary Conditions.

Authors:  Amirtahà Taebi; Rex M Pillai; Bahman S Roudsari; Catherine T Vu; Emilie Roncali
Journal:  Bioengineering (Basel)       Date:  2020-06-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.